Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.71 |
| ▸ | CA2 | P00918 | 8/20 | 0.71 |
| ▸ | CA9 | Q16790 | 6/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 5/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | CA3 | P07451 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA6 | P23280 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28326326 | 0.92 | HTT (0.66) | CA1CA2CA9HTTCA12 | |
| SCHEMBL28326328 | 0.91 | HTT (0.64) | CA1CA2CA9HTTCA12 | |
| SCHEMBL7527679 | 0.88 | CA1 (0.62) | CA1CA2CA9HTTCA12 | |
| SCHEMBL28363779 | 0.88 | CA1 (0.62) | CA1CA2CA9HTTCA12 | |
| Potassium Ion SCHEMBL1902294 | 0.83 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| SCHEMBL3519559 | 0.83 | CA2 (1.00) | CA1CA2CA9HTTCA12 | |
| SCHEMBL8690274 | 0.83 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| SCHEMBL866411 | 0.83 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| SCHEMBL31634023 | 0.83 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| SCHEMBL11704991 | 0.83 | CA1 (0.67) | CA1CA2CA9HTTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250290051-A1 | MUTATED SULFOTRANSFERASES AND USES THEREOF | SANOFI SA (FR) | 2025-09-18 | — | — | US | claimed |
| US-20250012802-A1 | SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO ORAL MINOXIDIL FOR THE TREATMENT OF ANDROGENETIC ALOPECIA | FOLLEA INTERNATIONAL | 2025-01-09 | — | — | US | claimed |
| EP-4488388-A1 | SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO ORAL MINOXIDIL FOR THE TREATMENT OF ANDROGENETIC ALOPECIA | Follea International (US) | 2025-01-08 | — | — | EP | claimed |
| CN-119265294-A | Methods and systems for predicting the response of oral minoxidil to treatment of androgenic alopecia | 芙丽亚国际公司 | 2025-01-07 | — | — | CN | claimed |
| CN-118339282-A | Use and method of sulfating a substrate with a mutated arylsulftransferase | 赛诺菲 | 2024-07-12 | — | — | CN | claimed |
| US-20240093166-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-03-21 | — | — | US | claimed |
| US-20240076634-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-03-07 | — | — | US | claimed |
| US-20240002819-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-01-04 | — | — | US | claimed |
| US-20230340552-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | GINKGO BIOWORKS, INC. | 2023-10-26 | — | — | US | claimed |
| US-11773382-B2 | Engineered aryl sulfate-dependent enzymes | OPTIMVIA, LLC (US) | 2023-10-03 | — | — | US | claimed |
| EP-2084294-A2 | STERILIZATION INDICATOR | American Sterilizer Company (US) | 2009-08-05 | — | — | EP | claimed |
| US-20090117603-A1 | STERILIZATION INDICATOR | FRANCISKOVICH PHILLIP P | 2009-05-07 | — | — | US | claimed |
| WO-2008082728-A2 | STERILIZATION INDICATOR | AMERICAN STERILIZER COMPANY (US) | 2008-07-10 | — | — | WO | claimed |
| WO-2008079469-A2 | GENETICALLY ENGINEERED BIOLOGICAL INDICATOR | AMERICAN STERILIZER COMPANY (US) | 2008-07-03 | — | — | WO | claimed |
| US-20080070231-A1 | Reporter genes taken up by microorganism, and repressor gene inhibits expression | AMERICAN STERILIZER COMPANY | 2008-03-20 | — | — | US | claimed |
| US-20080070272-A1 | STERILIZATION INDICATOR | AMERICAN STERILIZER COMPANY | 2008-03-20 | — | — | US | claimed |
| US-20050255562-A1 | Methods for synthesis of sulfated saccharides | NATIONAL INSTITUTES OF HEALTH | 2005-11-17 | — | — | US | claimed |
| US-6255088-B1 | Enzymatic sulfation of biomolecules | THE SCRIPPS RESEARCH INSTITUTE | 2001-07-03 | — | — | US | claimed |
| EP-1005098-A2 | Alkali metal electrochemical cell having an improved cathode activated with a nonaqueous electrolyte having a passivation inhibitor additive | WILSON GREATBATCH LTD. (US) | 2000-05-31 | — | — | EP | claimed |
| US-5500668-A | INK JET PRINTING | XEROX CORPORATION (US) | 1996-03-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340552-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | CSGALNACT1, NANS, STS | CA1 1261/4885CA2 1650/4885CA9 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.